Baltimore Washington Financial Advisors Inc. Has $10.73 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Share on StockTwits

Baltimore Washington Financial Advisors Inc. cut its stake in Johnson & Johnson (NYSE:JNJ) by 6.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 73,549 shares of the company’s stock after selling 4,702 shares during the period. Johnson & Johnson makes up 1.6% of Baltimore Washington Financial Advisors Inc.’s holdings, making the stock its 23rd largest position. Baltimore Washington Financial Advisors Inc.’s holdings in Johnson & Johnson were worth $10,728,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Fisher Asset Management LLC lifted its position in Johnson & Johnson by 2.0% during the 3rd quarter. Fisher Asset Management LLC now owns 12,081,488 shares of the company’s stock worth $1,563,103,000 after buying an additional 240,367 shares in the last quarter. California Public Employees Retirement System lifted its position in Johnson & Johnson by 16.9% during the 3rd quarter. California Public Employees Retirement System now owns 10,198,888 shares of the company’s stock worth $1,319,532,000 after buying an additional 1,477,454 shares in the last quarter. California State Teachers Retirement System lifted its position in Johnson & Johnson by 0.5% during the 3rd quarter. California State Teachers Retirement System now owns 4,890,440 shares of the company’s stock worth $632,725,000 after buying an additional 25,437 shares in the last quarter. Rhumbline Advisers lifted its position in Johnson & Johnson by 1.7% during the 3rd quarter. Rhumbline Advisers now owns 4,271,311 shares of the company’s stock worth $552,622,000 after buying an additional 72,582 shares in the last quarter. Finally, Great West Life Assurance Co. Can lifted its position in Johnson & Johnson by 4.5% during the 3rd quarter. Great West Life Assurance Co. Can now owns 4,037,141 shares of the company’s stock worth $522,998,000 after buying an additional 173,747 shares in the last quarter. 67.38% of the stock is owned by hedge funds and other institutional investors.

Shares of JNJ stock opened at $150.09 on Friday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.00 and a current ratio of 1.26. The firm’s 50-day moving average is $148.01 and its 200-day moving average is $136.74. The stock has a market cap of $399.68 billion, a price-to-earnings ratio of 22.14, a PEG ratio of 2.53 and a beta of 0.69. Johnson & Johnson has a 52-week low of $126.10 and a 52-week high of $154.50.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, January 22nd. The company reported $1.88 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.87 by $0.01. The company had revenue of $20.75 billion for the quarter, compared to analysts’ expectations of $20.83 billion. Johnson & Johnson had a net margin of 22.18% and a return on equity of 39.30%. Johnson & Johnson’s quarterly revenue was up 1.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.97 EPS. Sell-side analysts predict that Johnson & Johnson will post 9.03 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 25th will be issued a $0.95 dividend. The ex-dividend date is Monday, February 24th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 2.53%. Johnson & Johnson’s payout ratio is 43.78%.

Several equities research analysts have commented on JNJ shares. Morgan Stanley raised shares of Johnson & Johnson from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $145.00 to $170.00 in a research report on Tuesday, December 17th. Barclays raised shares of Johnson & Johnson from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $140.00 to $173.00 in a research report on Thursday, December 19th. Wells Fargo & Co boosted their price target on shares of Johnson & Johnson from $155.00 to $165.00 and gave the stock an “overweight” rating in a research report on Thursday, January 9th. Raymond James boosted their price target on shares of Johnson & Johnson from $147.00 to $161.00 and gave the stock an “outperform” rating in a research report on Thursday, January 23rd. Finally, Credit Suisse Group boosted their price target on shares of Johnson & Johnson from $163.00 to $170.00 and gave the stock an “outperform” rating in a research report on Monday, January 27th. Three equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $161.92.

In other news, EVP Kathryn E. Wengel sold 2,017 shares of the company’s stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $141.07, for a total value of $284,538.19. Following the sale, the executive vice president now directly owns 51,736 shares of the company’s stock, valued at approximately $7,298,397.52. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, COO Michael E. Sneed sold 58,128 shares of the company’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $149.39, for a total transaction of $8,683,741.92. Following the completion of the sale, the chief operating officer now directly owns 107,511 shares in the company, valued at $16,061,068.29. The disclosure for this sale can be found here. 0.23% of the stock is currently owned by corporate insiders.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Further Reading: What is a capital gain?

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

GAM Holding AG Decreases Holdings in Lear Co.
GAM Holding AG Decreases Holdings in Lear Co.
GAM Holding AG Makes New Investment in FirstEnergy Corp.
GAM Holding AG Makes New Investment in FirstEnergy Corp.
GAM Holding AG Sells 1,916 Shares of Constellation Brands, Inc.
GAM Holding AG Sells 1,916 Shares of Constellation Brands, Inc.
GAM Holding AG Reduces Stock Position in Philip Morris International Inc.
GAM Holding AG Reduces Stock Position in Philip Morris International Inc.
GAM Holding AG Makes New $332,000 Investment in Nordson Co.
GAM Holding AG Makes New $332,000 Investment in Nordson Co.
Cracker Barrel Old Country Store, Inc.  Shares Sold by GAM Holding AG
Cracker Barrel Old Country Store, Inc. Shares Sold by GAM Holding AG


 
© 2006-2020 Zolmax.